Inventor
LANG MARC
FR34 patents
⚠️ This page may combine multiple inventors who share the name “LANG MARC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CIBA GEIGY CORP
19 patentsUS5670497ASep 23, 1997
Cyclic hydrazine compounds
CIBA GEIGY CORP66 citations96
US5073574ADec 17, 1991
Tetrazolyl substituted benzonitriles and anti-tumor use thereof
CIBA GEIGY CORP23 citations92
US5663200ASep 2, 1997
Antiviral ethers of aspartate protease substrate isosteres
CIBA GEIGY CORP28 citations91
US5643878AJul 1, 1997
5-amino-4-hydroxyhexanoic acid derivatives
CIBA GEIGY CORP25 citations91
US5637605AJun 10, 1997
α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
CIBA GEIGY CORP12 citations74
US5409927AApr 25, 1995
Morpholin- and thiomorpholin-4-ylamides
CIBA GEIGY CORP7 citations74
US5378721AJan 3, 1995
Heteroarylmethylbenzenes
CIBA GEIGY CORP10 citations74
US5376669ADec 27, 1994
α-fluoro-α-(1,2,3-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
CIBA GEIGY CORP8 citations74
US5227393AJul 13, 1993
α-fluoro-α-tetrazolyl-phenylmethyl derivatives useful as aromatase inhibitors
CIBA GEIGY CORP9 citations74
US4826832AMay 2, 1989
Penen compounds
CIBA GEIGY CORP7 citations74
US4656165AApr 7, 1987
Aminomethyl penem compounds
CIBA GEIGY CORP6 citations74
US4952690AAug 28, 1990
6-substituted thia-aza compounds
CIBA GEIGY CORP12 citations73
US4692442ASep 8, 1987
6-substituted penem compounds
CIBA GEIGY CORP14 citations73
US5457209AOct 10, 1995
4-[α(cyanophenyl)-1-(1,2,3-triazolyl)methyl]-benzonitrile
CIBA GEIGY CORP3 citations63
US5246952ASep 21, 1993
Heteroarylmethylbenzenes
CIBA GEIGY CORP2 citations63
US5206256AApr 27, 1993
Naphthalene derivatives
CIBA GEIGY CORP5 citations63
US4965260AOct 23, 1990
Bicyclic beta-lactam carboxylic acids
CIBA GEIGY CORP3 citations63
US4616007AOct 7, 1986
Heterocyclthio compounds, process for their manufacture, pharmaceutical preparations that contain these compounds, and the the use of the latter
CIBA GEIGY CORP2 citations63
US5663168ASep 2, 1997
Use of compositions for combating tumour diseases
CIBA GEIGY CORP4 citations56
NOVARTIS AG
7 patentsUS5981533ANov 9, 1999
Pyrazole derivatives and processes for the preparation thereof
NOVARTIS AG104 citations98
US6251911B1Jun 26, 2001
Pyrimidine derivatives and processes for the preparation thereof
NOVARTIS AG64 citations96
US6180636B1Jan 30, 2001
Substituted pyrrolopyrimidines and processes for their preparation
NOVARTIS AG78 citations96
US5753652AMay 19, 1998
Antiretroviral hydrazine derivatives
NOVARTIS AG49 citations92
US5935976AAug 10, 1999
Antiviral ethers of aspartate protease substrate isosteres
NOVARTIS AG18 citations91
US6225345B1May 1, 2001
Azahexane derivatives as substrate isosters of retroviral asparate proteases
NOVARTIS AG13 citations73
US6933290B2Aug 23, 2005
2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
NOVARTIS AG1 citations51
NOVARTIS FINANCE CORP
4 patentsUS5849911ADec 15, 1998
Antivirally active heterocyclic azahexane derivatives
NOVARTIS FINANCE CORP130 citations98
US6110946AAug 29, 2000
Antivirally active heterocyclic azahexane derivatives
NOVARTIS FINANCE CORP11 citations81
US6300519B1Oct 9, 2001
Antivirally active heterocyclic azahexane derivatives
NOVARTIS FINANCE CORP9 citations73
US6166004ADec 26, 2000
Combinations of HIV protease inhibitors with reverse transcriptase inhibitors
NOVARTIS FINANCE CORP6 citations73